+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 45Years - 65Years
FEMALE
Healthy Volunteers
ID07728175

Study of Sirolimus Effects on Brain Blood Flow in Middle-Aged Women with ApoE4 Gene

Led by University of Missouri-Columbia · Updated on 2026-10-05

225

Participants Needed

1

Research Sites

27 weeks

Total Duration

AI-Summary

What This Trial Is About

Alzheimers disease is a severe brain condition marked by harmful clumps and fibers in the brain, with no current cure. This trial studies sirolimus, an FDA-approved drug that might improve brain blood flow and energy use. It focuses on women aged 45 to 65 who carry the ApoE4 gene, which raises Alzheimers risk. The study is randomized and placebo-controlled to compare sirolimus with a non-medicine pill. Participants will be randomly assigned to receive either sirolimus or a placebo daily by mouth for about 4 weeks. The trial includes three visits over 12 weeks. During the study, participants will complete questionnaires, undergo genetic testing for the ApoE4 gene, provide blood samples and vital signs, and have two MRI scans to measure brain blood flow and other brain functions. Throughout the study, participants will keep a diary to record when they take the study drug or placebo. Researchers will measure changes in cerebral blood flow using MRI from baseline to 4 weeks as the primary outcome. Secondary outcomes include blood markers, brain connectivity by fMRI, blood brain barrier integrity, brain oxygenation, and glucose uptake by PET imaging. Safety and adherence will be monitored during the trial period.

CONDITIONS

Brief Title

Effects of Sirolimus on Asymptomatic ApoE4 Carriers

Research Team

K

Kim Ray

N

Nathan Bresette

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here